Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.
Gorlin-Goltz syndrome, also referred to as naevoid basal cell carcinoma syndrome (NBCCS), is an autosomal dominant skin disease with complete penetrance and inconstancy of the four major findings: multiple naevoid basal cell carcinomas (BCCs), pits on palms and soles, skeletal abnormalities (for example, jaw cysts), and ectopic calcification. The treatment of multiple BCCs is still a matter of debate. We report three cases of multiple BCCs in Gorlin-Goltz syndrome treated with topical 5% imiquimod cream, an immune response modifier. Patients were successfully cleared of BCCs after treatment for 6-8 weeks. Histologically no apparent signs of BCC-persistence could be detected and no recurrences were detected during the 12 month follow up period.
Stockfleth
Eggert
E
Department of Dermatology of the Charité, Humboldt University, Schumannstra e 20/21, 10117 Berlin, Germany. E.Stockfleth@web.de
Ulrich
Claas
C
Hauschild
Axel
A
Lischner
Stephan
S
Meyer
Thomas
T
Christophers
Enno
E
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000634:Aminoquinolines / Q000008:administration & dosage*; D001478:Basal Cell Nevus Syndrome / Q000188:drug therapy* / Q000473:pathology; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005145:Face; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077271:Imiquimod; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D012494:Sampling Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000634:Aminoquinolines; D000077271:Imiquimod